[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Beneficência Portuguesa de São Paulo\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":152},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,42,67,95,125],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100548844","effectiveness-of-the-brazilian-diabetes-prevention-program-100548844",false,"NCT06426277","Effectiveness of the Brazilian Diabetes Prevention Program","Effectiveness of the Diabetes Prevention Program on the Incidence of Type 2 Diabetes Mellitus Among Brazilian Individuals: Randomized Clinical Trial (PROVEN-DIA Study)","PROVEN-DIA","Inclusion Criteria\n\n* Be 18 years or older (no maximum age for being eligible)\n* Have a body mass index (BMI) between 18,5 and 34,9kg\u002Fm²\n* Have, at least, one electronic device (includes any of the following devices):\n\n  * Computer\n  * Laptop\u002Fnotebook\n  * Tablet\n  * Smartphone\n* Have access to internet (broadband, 3G, 4G, 5G, among others) Without previous nutritional counseling (within the 6 months prior to recruitment\u002Frandomization\u002Fintervention) Without supervision by a Physical Education Professional (Personal Trainer) in the past 6 months\n* Living near the research center (at maximum 60 minutes)\n* Diagnosis of prediabetes defined as two HbA1c measurements between 5.7% and 6.4% collected 7 to 90 days apart.\n\nExclusion Criteria:\n\n* Diagnosis of Diabetes Mellitus (including current or recent use, within three months, of glucose-lowering medication)\n* Underlying disease likely to limit life expectancy and\u002For increase the risk of interventions influencing the risk of developing T2D\n* Diagnosis of Renal Disease\n* Diagnosis of Pulmonary Disease\n* Gastrointestinal Disease\n* Secondary prevention for Cardiovascular Disease\n* Endocrine Diseases\n* Weight loss exceeding 10% in the last 6 months (except postpartum-related)\n* Uncontrolled Hypertension\n* Diagnosis of Polycystic Ovary Syndrome (self-reported)\n* Patients undergoing treatment for Tuberculosis (except those using isoniazid \\[INH\\] as prophylaxis)\n* Presence of diseases that may severely reduce life expectancy or the ability to participate in the study\n* Pregnant or breastfeeding women\n* Severe psychiatric disorders that, in the opinion of the clinical team, hinder participation in the program\n* Acute or chronic excessive alcohol consumption\n* Congestive Heart Failure (CHF) with a New York Heart Association Functional Class (NYHA) \\> 2\n* Need for referral to a cardiologist according to the Physical Activity Readiness Questionnaire (PAR-Q)\n* Current or recent participation (within the last six months) in another clinical trial that impacts the interventions and\u002For is associated with the study outcomes (in case of doubt, contact the coordinating center)\n* Likely relocation away from the research collaborating center within the next 3 years\n* Another household member is a participant or a team member of the PROVEN-DIA study\n* Unwillingness to accept treatment assignment by randomization and\u002For refusal to participate in the study (signing the Informed Consent Form)\n* Continuous use of the following medications:\n\nCorticosteroids other than topical, ophthalmic, or inhaled preparations Antineoplastic agents Psychoactive agents Other medications.\n\n• Participant from the pilot Randomized Clinical Trial (Brazilian Diabetes Prevention Program: Pilot Study (PROVEN-Dia), NCT05689658)","ALL","18 Years",{"count":20,"type":21},1305,"ESTIMATED","INTERVENTIONAL",[24],"NA","The aim of this multicenter, randomized controlled trial is to assess the effectiveness of the Brazilian Diabetes Prevention Program (delivered face-to-face or via e-health) in preventing type 2 diabetes (T2D) in at least 1,305 adults at high risk of T2D over a 3-year follow-up period. Our outcomes include the incidence of T2D, body weight (kg), BMI, glycemic biomarkers, use of antidiabetic drugs, the proportion of individuals achieving controlled glycemia or HbA1c levels without medication, diet quality, moderate-to-vigorous physical activity (min\u002Fweek), prevalence of physical inactivity, sleep quality, perceived stress, alcohol consumption, smoking, and quality of life. In addition, social, cultural, educational, and geographical factors at the community level will be analyzed throughout the follow-up to determine their association with the incidence of T2D.",[27,28],"Prediabetic State","Pre Diabetes","RECRUITING","2026-06-22",{"date":32,"type":33},"2026-06-25","ACTUAL",{"date":35,"type":33},"2024-12-01",{"date":37,"type":21},"2029-12-31",{"name":39,"class":40},"Beneficência Portuguesa de São Paulo","OTHER",2,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":48,"targetDuration":4,"studyType":50,"phases":4,"briefSummary":51,"conditions":52,"keywords":54,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":66},"100644417","development-of-a-pharmacogenomic-panel-for-early-detection-of-chemotherapy--and-immunotherapy-induced-cardiotoxicity-100644417","NCT07663357","Development of a Pharmacogenomic Panel for Early Detection of Chemotherapy- and Immunotherapy-Induced Cardiotoxicity.","Inclusion Criteria:\n\n* Patients with a confirmed diagnosis of breast cancer who are scheduled to initiate treatment with anthracyclines and\u002For HER2-targeted therapies (anti-HER2 therapies).\n\nExclusion Criteria:\n\n* Patients with a left ventricular ejection fraction (LVEF) \\\u003C 50%;\n* Patients who have undergone chemotherapy and\u002For radiotherapy within the previous year;\n* Patients with chronic kidney disease and a glomerular filtration rate (GFR) \\\u003C 30 mL\u002Fmin\u002F1.73 m²;\n* Patients with uncontrolled hypertension;\n* Patients with complex congenital heart disease.",{"count":49,"type":21},1000,"OBSERVATIONAL","To evaluate the use of a pharmacogenetic and pharmacoepigenetic panel for predicting chemotherapy- and immunotherapy-induced cardiotoxicity in cancer patients.",[53],"Cardiotoxicity",[55,53,56,57],"oncology","pharmacogenomics","epigenomics","2026-06-17",{"date":60,"type":33},"2026-06-23",{"date":62,"type":33},"2026-05-11",{"date":64,"type":21},"2029-12-30",{"name":39,"class":40},6,{"id":68,"slug":69,"hasResults":11,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":73,"eligibilityCriteria":74,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":75,"targetDuration":4,"studyType":22,"phases":77,"briefSummary":79,"conditions":80,"keywords":82,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":94},"100542380","phase-4-ceftolozanetazobactam-versus-meropenem-for-febrile-neutropenia-on-patients-colonized-with-or-at-risk-for-infection-with-extended-spectrum-beta-lactamase---producing-pathogens-100542380","NCT06342115","Ceftolozane\u002FTazobactam Versus Meropenem for Febrile Neutropenia on Patients Colonized With or at Risk for Infection With Extended Spectrum Beta Lactamase - Producing Pathogens","Ceftolozane\u002FTazobactam Versus Meropenem for Febrile Neutropenia on Patients Colonized With or at Risk for Infection With Extended Spectrum Beta Lactamase (ESBL)-Producing Pathogens: a Randomized Double-blind Non-inferiority Trial.","CLEMENT","Inclusion criteria:\n\n\\- Individuals who present with the onset of febrile neutropenia and at the same time present colonization with an ESBL-producing pathogen (identified through positive routine rectal swabs and\u002For positive culture of clinical specimen) or risk of infection with an ESBL-producing pathogen (use of 3rd\u002F4th gen cephalosporin or piperacillin\u002Ftazobactam for at least 48 hours in the last 30 days).\n\nExclusion Criteria:\n\n* Patients known to be colonized with carbapenem-resistant or CEF\u002FTAZ-resistant pathogens\n* Patients with previous use of carbapenems for at least 48h in the past 30 days are also excluded due to risk of resistance to the study drugs.\n* Growth of a pathogen resistant to either study drug in a relevant clinical specimen during the intervention phase will be followed by adjustment of therapy according to local protocol, unblinding, and exclusion from the study.\n* Patients that have received less than 72h of either study drug will also be excluded from the final analyses.",{"count":76,"type":21},176,[78],"PHASE4","The study proposes a planned, double-blind, non-inferiority clinical trial involving patients with febrile neutropenia and risk of extended-spectrum beta-lactamase (ESBL) infection. The goal is:\n\n\\- Analyze the efficacy and tolerability of Ceftolozane\u002Ftazobactam (CEF\u002FTAZ) compared to the current standard of care (meropenem) in patients with febrile neutropenia and risk of ESBL infection.\n\nPatients will be randomly assigned to receive CEF\u002FTAZ or meropenem, with assessment of clinical response, toxicity and microbiological evolution. Stool samples will be collected before, during and after treatment for intestinal microbiota analysis and intestinal microbiome analysis to evaluate possible effects on GVHD. Analysis of the results will include the taxonomic classification of the organisms present. Data will be analyzed to assess non-inferiority in clinical response, incidence of GVHD, antimicrobial resistance and other outcomes.",[81],"Febrile Neutropenia",[81,83,84,85],"Ceftolozane\u002Ftazobactam","ESBL","Meropenem","2025-04-30",{"date":88,"type":33},"2025-05-02",{"date":90,"type":33},"2025-03-26",{"date":92,"type":21},"2026-12",{"name":39,"class":40},1,{"id":96,"slug":97,"hasResults":11,"nctId":98,"briefTitle":99,"officialTitle":99,"acronym":100,"eligibilityCriteria":101,"healthyVolunteers":11,"sex":102,"minAge":18,"maxAge":4,"enrollmentInfo":103,"targetDuration":4,"studyType":22,"phases":105,"briefSummary":106,"conditions":107,"keywords":110,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":117,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":124},"100460615","wearable-enhanced-fitness-tracking-for-metastatic-breast-cancer-patients-using-endocrine-treatment-and-palbociclib-100460615","NCT05277935","Wearable Enhanced Fitness Tracking for Metastatic Breast Cancer Patients Using Endocrine Treatment and Palbociclib","WEFITTER","Inclusion Criteria:\n\n* Female patients ≥ 18 years of age diagnosed with hormone receptor-positive\u002F human epidermal growth factor receptor 2- negative metastatic breast cancer undergoing treatment with Palbociclib combined with aromatase inhibitors (letrozole, exemestane or anastrozole) or fulvestrant as first-line therapy, or in treatment with Palbociclib and fulvestrant as second-line or posterior-line therapy in the metastatic setting; may be using ovarian suppression if the patient is premenopausal.\n* The patient must be on treatment for at least three (3) months with Palbociclib and endocrine therapy.\n* Evidence of a signed and dated informed consent document, physically or digitally, indicating that the research participant was informed about all relevant aspects of the study;\n* The patient agrees not to participate in another study with drug intervention while on treatment.\n* Have performance status according to the Eastern Cooperative Oncology Group\n* Have access to a compatible smartphone and 3G or 4G internet connection\n\nExclusion Criteria:\n\n* Patients considered to be at poor medical risk due to uncontrolled serious medical disorder, non-malignant systemic disease, or active uncontrolled infection. Examples: uncontrolled ventricular arrhythmia, recent myocardial infarction (within 6 months), stroke, gastrointestinal bleeding, or any psychiatric disorder that precludes informed consent; between others.\n* Patients who have a life expectancy of \\\u003C 3 months.\n* Treatment with any product under investigation during the last 28 days;\n* Another acute or chronic medical or psychiatric condition or severe laboratory abnormality that could increase the risk associated with participation in the study or that Page 10 de 21 Version 6.0 could interfere with the interpretation of the study results and, in the investigator's judgment, would make the research participant unsuitable for inclusion in the study. study.\n* Illiterate patients or those with a low level of education that may prevent the correct use of the Wecancer application and\u002For the watch with monitoring of physical activity.","FEMALE",{"count":104,"type":21},68,[24],"Combining a fitness tracker technology with real-time patient-reported outcome monitoring associated with interventions through a health care app is a novel strategy to evaluate metastatic breast cancer patients using Palbociclib and endocrine treatment.",[108,109],"Breast Neoplasm Female","Quality of Life",[111,112,113,114,115],"Quality of life","Metastatic breast cancer","Metastasis","Exercise","Palbociclib","2024-08-23",{"date":118,"type":33},"2024-08-26",{"date":120,"type":33},"2022-04-22",{"date":122,"type":21},"2025-03-01",{"name":39,"class":40},4,{"id":126,"slug":127,"hasResults":11,"nctId":128,"briefTitle":129,"officialTitle":130,"acronym":4,"eligibilityCriteria":131,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":132,"targetDuration":4,"studyType":22,"phases":134,"briefSummary":135,"conditions":136,"keywords":138,"overallStatus":143,"whyStopped":4,"lastUpdateSubmitDate":144,"lastUpdatePostDateStruct":145,"startDateStruct":147,"completionDateStruct":149,"leadSponsor":151,"locationsCount":4},"100547790","effect-of-a-bundle-of-interventions-on-the-outcomes-of-patients-with-intracranial-devices-icp-monitor-e-evd-100547790","NCT06412549","Effect of a Bundle of Interventions on the Outcomes of Patients With Intracranial Devices (ICP Monitor e EVD)","IMPACTO MR: Effect of a Bundle of Interventions on Patients With Central Nervous System Devices - Project Platform Supporting the National Action Plan for Prevention and Control of Antimicrobial Resistance","Inclusion Criteria:\n\n* Adult patients with intracranial pressure monitoring catheters (intraventricular or intraparenchymal) and\u002For external ventricular drain.\n* The patient can be included from the moment the catheter is implanted, without there being a minimum time for inclusion.\n\nExclusion Criteria:\n\n* Suspected or confirmed brain death.",{"count":133,"type":21},1300,[24],"Non-randomized clinical trial conducted in the adult ICUs of Brazilian hospitals participating in the IMPACTO MR Platform, involving adult patients using an intracranial pressure monitoring catheter device or external ventricular drain.\n\nThe study will test the hypothesis that the intervention bundle, following ANVISA recommendations for care practices, will reduce the rates of central nervous system infections associated with ICP and EVD devices.\n\nThis reduction is expected to lead to more accurate diagnoses, decreased antibiotic usage, shortened ICU and hospital stays, and reduced hospital costs.",[137],"Central Nervous System Infections",[139,140,141,142],"Bacterial resistance","Health care","Central nervous systen infection","Multi-resistant microorganism","NOT_YET_RECRUITING","2024-05-08",{"date":146,"type":33},"2024-05-14",{"date":148,"type":21},"2024-06-01",{"date":150,"type":21},"2026-12-31",{"name":39,"class":40},""]